The European Commission has agreed with a sixth pharmaceutical company to supply coronavirus vaccines as they become available and prove safe and effective.
It concerns a deal with the German-American combination BioNTech-Pfizer for 200 million doses and an option for 100 million doses.
The vaccines can be purchased by the 27 member states, who can use them for their own use or donate them to poorer countries.
With the agreement, the vaccine portfolio put together by Brussels is complete, reports the daily EU board. EU Commissioner Stella Kyriakides (Public Health): “We are optimistic that among these candidates is a safe and effective vaccine against Covid-19 that will help us defeat this pandemic.”
The committee previously entered into agreements with Sanofi and GlaxoSmithKline (GSK), Janssen Vaccines in Leiden, CureVac, Moderna and AstraZeneca.
The latter vaccine developer, a collaboration between the British-Swedish pharmaceutical company AstraZeneca and the University of Oxford, announced on Wednesday that the trials with the vaccine were halted because a test subject has contracted a “potentially unexplained condition”.
They first want to know whether it is due to the vaccine before continuing with their trial.